Dendreon price target lowered to $6.50 from $9 at Bernstein

Bernstein reduced its price target on Dendreon after the company reported lower than expected Q1 revenue. The firm lacks confidence in the company's strategy for selling Provenge, but it still thinks the drug has potential and keeps an Outperform rating on the shares.

View Comments (0)